¶ PRP (Platelet-Rich Plasma)
| Indication | Orthopedic, Dermatologic, Fertility |
| Access | Rx / Clinical Procedure |
| Dosing Sched | Monthly to Annually (Condition Dependent) |
| Safety Profile | Low (Autologous) |
| Key Marker | Platelet Concentration (x baseline) |
| Est. Cost | $500–$2,500 per session |
Platelet-Rich Plasma (PRP) is an autologous blood product containing a supra-physiological concentration of platelets and their associated growth factors. Used across orthopedics, dermatology, and increasingly in reproductive medicine, PRP therapy aims to harness the body's natural healing capabilities by delivering a potent cocktail of bioactive proteins directly to sites of injury or age-related degeneration.
¶ At a glance
Key points (high-level summary)
- Regenerative Potential: Utilizes a patient's own blood components to stimulate tissue repair and regeneration.
- Broad Applications: Effective in treating conditions ranging from knee osteoarthritis and tendinopathies to hair loss and skin rejuvenation.
- Safety: Very low risk of adverse reactions due to its autologous nature.
What people use it for
- Main goals: Joint pain reduction, tissue healing, hair regrowth, skin quality improvement, fertility enhancement.
- Evidence quality: Moderate to High, depending on the specific condition and PRP preparation method.
¶ What is PRP?
¶ Definition and Composition
PRP is defined as a volume of autologous plasma with a platelet concentration typically 3 to 5 times above baseline (150,000 to 400,000/µL). A therapeutic PRP preparation often targets a concentration of at least 1,000,000 platelets/µL[1].
The composition of PRP is not limited to platelets and can vary significantly with preparation methods, potentially including:
- White Blood Cells (Leukocytes): Neutrophils, monocytes, and lymphocytes, which can influence inflammatory responses.
- Red Blood Cells (RBCs): Generally minimized to prevent pro-inflammatory effects.
- Plasma Proteins: Fibrinogen, albumin, and globulins, which provide a biological scaffold for healing.
¶ The "Platelet" in PRP
Platelets are anucleate cell fragments derived from megakaryocytes. Beyond their primary role in hemostasis, they serve as crucial reservoirs of growth factors (GFs) and cytokines stored in intracellular α-granules. Upon activation, these granules degranulate, releasing their bioactive contents to initiate and modulate the healing cascade[2].
¶ Preparation Methods
The efficacy of PRP is highly dependent on its preparation, which currently lacks universal standardization. The general procedure includes:
- Venipuncture: Collection of 10–60 mL of whole blood into tubes with an anticoagulant (e.g., acid citrate dextrose or sodium citrate).
- Centrifugation: The blood is spun to separate components by density.
- Single-Spin: Typically yields lower platelet concentrations (1.5–3x baseline), separating red blood cells from plasma/platelets.
- Double-Spin: Involves an initial spin to separate RBCs, followed by a second spin to concentrate platelets from the plasma, often achieving higher concentrations (4–8x baseline)[3].
- Extraction: The platelet-rich layer (buffy coat or plasma layer) is then harvested.
¶ Classification: Leukocyte-Rich vs. Leukocyte-Poor
The leukocyte content is a critical differentiator for PRP preparations:
- Leukocyte-Rich PRP (LR-PRP): Contains high levels of white blood cells. While potentially initiating an inflammatory "re-start" useful in chronic tendinopathies, it can also release pro-inflammatory cytokines (IL-1β, TNF-α) and proteases[4].
- Leukocyte-Poor PRP (LP-PRP): Most leukocytes are removed. This type is generally preferred for intra-articular injections (e.g., knee osteoarthritis) to minimize post-injection pain and synovial inflammation[5][6]. For Achilles tendinopathy, LP-PRP is superior to LR-PRP to avoid exacerbating inflammation[7].
¶ Mechanisms of Action
PRP's therapeutic effects stem from the local delivery of numerous growth factors (GFs) that orchestrate key phases of tissue repair and regeneration. Upon activation, platelets release a concentrated array of these factors:
| Growth Factor | Primary Function |
|---|---|
| PDGF (Platelet-Derived Growth Factor) | Chemotaxis for macrophages/fibroblasts; stimulates collagen synthesis, proliferation, and matrix remodeling. |
| TGF-β (Transforming Growth Factor-beta) | Regulates cell proliferation, differentiation, and extracellular matrix (ECM) production. |
| VEGF (Vascular Endothelial Growth Factor) | Potent stimulator of angiogenesis (new blood vessel formation) to improve tissue vascularization. |
| IGF-1 (Insulin-like Growth Factor 1) | Promotes cell survival, proliferation, and synthesis of proteins, including collagen. |
| EGF (Epidermal Growth Factor) | Stimulates epithelial cell proliferation, migration, and differentiation, crucial for wound closure. |
Biological Effects:
- Inflammation Modulation: While LR-PRP can be initially pro-inflammatory, PRP also releases anti-inflammatory cytokines (e.g., IL-1RA) and lipoxins, contributing to inflammation resolution[2:1].
- Cell Proliferation and Recruitment: GFs attract local stem cells, fibroblasts, and other progenitor cells to the injury site, accelerating cellular regeneration.
- Angiogenesis: Enhanced blood supply through new vessel formation improves nutrient and oxygen delivery, critical for healing.
- Extracellular Matrix Remodeling: Stimulates the synthesis of collagen, proteoglycans, and hyaluronic acid, essential components of healthy tissue structure[2:2].
¶ Evidence summary table (human outcomes)
| Outcome / Goal | Effect* | Consistency** | Evidence quality | Trials*** | Notes (population, duration, dose) |
|---|---|---|---|---|---|
| Knee Osteoarthritis (Pain & Function) | High | High | 10+ RCTs, 3+ meta-analyses | Clinically significant improvement in pain and function at 6-12 months; LP-PRP generally preferred[5:1][8] | |
| Tendinopathy (Pain & Function) | Moderate | Moderate | 5+ RCTs, 2+ meta-analyses | Effective for chronic lateral epicondylitis; mixed results for other tendinopathies. LR-PRP often used[4:1][9][7:1] | |
| Androgenetic Alopecia (Hair Density) | High | Moderate | 5+ RCTs, 1 meta-analysis | Significant increase in hair density and count, comparable to or better than minoxidil[10] | |
| Skin Rejuvenation (Elasticity & Wrinkles) | High | Moderate | 9 RCTs, 1 meta-analysis | Significant improvements in skin elasticity, texture, and reduction of fine wrinkles[11][12] | |
| Chronic Wound Healing (Closure Rate) | High | High | 29 RCTs, 2 meta-analyses | 5.32 times higher odds of complete wound closure compared to standard care[13][14] | |
| Diminished Ovarian Reserve (Fertility) | Moderate | Moderate | 3+ RCTs, 2 meta-analyses | Increases ovarian reserve markers (AMH, AFC), mature oocyte yield, and pregnancy rates[15][16][17] |
- *Effect: Number of arrows (1-3) indicates magnitude. Direction: ↑ (increase), ↓ (decrease), = (no effect), ? (unclear). Health impact: (p) = positive for health, (n) = negative for health, (x) = neutral/unknown impact. Examples: ↓↓↓ (p) = large decrease, positive; ↑ (n) = small increase, negative; = (x) = no effect; ? = unclear.
- IMPORTANT: If using the compact renderer encoding (<effect ...>), do NOT include the text arrows or parentheses next to it. Just use the tag.
- **Consistency: Low (results conflict), Moderate (mixed but leaning one way), High (most trials agree)
- ***Trials: Number of RCTs or total trials informing this outcome (shows evidence depth at a glance)
- REQUIRED: You MUST include a citation key (e.g.
[^1]) in the "Notes" column for every single row. If you claim a result, you must link the specific Meta-Analysis or Key RCT that proves it.
¶ Evidence by Condition
¶ 1. Knee Osteoarthritis (OA)
Evidence Grade: High
PRP is a well-established intervention for mild-to-moderate knee OA (Kellgren-Lawrence grades 1–3).
- Efficacy: A 2025 meta-analysis confirmed PRP injections lead to clinically significant improvements in pain and function, outperforming placebo and hyaluronic acid, with benefits sustained for 6–12 months[5:2]. PRP has also demonstrated superiority to corticosteroids for long-term pain relief, avoiding potential cartilage degradation associated with steroids[8:1].
- Protocol: LP-PRP is generally preferred for intra-articular injections to minimize post-injection inflammation. Multiple injections (typically 2–3 spaced weekly or monthly) often yield superior and more durable results[6:1]. Combining PRP with hyaluronic acid may also offer synergistic benefits[18].
¶ 2. Tendinopathy
Evidence Grade: Moderate (Condition Dependent)
PRP's efficacy in tendinopathy varies by the specific tendon and chronicity.
- Lateral Epicondylitis (Tennis Elbow): This condition has the strongest evidence, with randomized controlled trials showing LR-PRP provides better long-term pain relief and functional improvement compared to corticosteroid injections[9:1][4:2].
- Achilles and Patellar Tendinopathy: Results are mixed. While some studies suggest benefit in chronic, recalcitrant cases, others show no significant difference from saline or exercise alone. For Achilles tendinopathy, LP-PRP is recommended to prevent exacerbation of inflammation[7:2].
¶ 3. Androgenetic Alopecia (Hair Loss)
Evidence Grade: Moderate
PRP is utilized to stimulate dormant hair follicle stem cells and extend the anagen (growth) phase of hair.
- Efficacy: A 2025 systematic review and meta-analysis found that PRP significantly increased hair density and hair count in both men and women with androgenetic alopecia. It is often used as an adjunct to other hair loss treatments like minoxidil or finasteride, with comparable or superior results to minoxidil alone[10:1].
- Protocol: Common protocols involve 3–4 initial monthly sessions, followed by maintenance treatments every 3–6 months.
¶ 4. Skin Rejuvenation
Evidence Grade: Moderate
Often branded as the "Vampire Facial" when combined with microneedling, PRP is used for overall skin texture and youthfulness.
- Effects: A 2024 meta-analysis demonstrated that PRP treatments significantly improve skin elasticity, reduce wrinkle volume, and enhance overall facial rejuvenation[11:1]. Combining PRP with microneedling or fractional laser has shown enhanced efficacy in improving atrophic acne scars and accelerating recovery times[12:1].
- Periorbital Rejuvenation: Reviews confirm significant improvements in hyperpigmentation and skin laxity in the delicate periorbital (around the eyes) region[19].
¶ 5. Chronic Wound Healing
Evidence Grade: High
PRP's rich growth factor profile makes it a compelling therapy for chronic, non-healing wounds.
- Efficacy: A large 2022 meta-analysis of 29 RCTs involving 2,198 wounds reported that PRP treatment led to 5.32 times higher odds of complete wound closure compared to standard wound care[14:1]. Both autologous and allogeneic PRP have shown high efficacy and safety in promoting healing in various chronic wound etiologies[13:1].
¶ 6. Diminished Ovarian Reserve & Infertility
Evidence Grade: Moderate
Emerging evidence suggests PRP may offer a breakthrough for women with diminished ovarian reserve (DOR) or poor ovarian response (POR) undergoing IVF.
- Efficacy: Clinical evidence, including a 2024 meta-analysis and a double-blind RCT, indicates that intraovarian autologous PRP infusion significantly increases ovarian reserve markers (AMH, Antral Follicle Count), improves mature oocyte yield, enhances embryo quality, and increases clinical pregnancy rates in DOR and POR patients[15:1][16:1][17:1]. This is attributed to the growth factors stimulating dormant follicles and improving ovarian microenvironment.
¶ Safety and Adverse Events
Since PRP is derived from the patient's own blood (autologous), the risk of immunogenic reactions, allergic responses, or disease transmission is virtually zero.
- Common Side Effects: The most frequent adverse events include localized pain, swelling, and stiffness at the injection site. These are usually mild and transient, lasting a few days, particularly with LR-PRP preparations. Bruising at the venipuncture or injection site is also common.
- Rare Complications:
- Infection: A risk with any injection procedure if sterile techniques are not rigorously followed.
- Nerve Injury: Possible, though rare, due to needle trauma.
- Ocular Complications: Extremely rare, but serious cases of unilateral visual loss following periorbital PRP injections have been reported due to retrograde ophthalmic artery embolization[20]. This highlights the importance of anatomical knowledge and careful technique in sensitive areas.
- Contraindications:
- Critical thrombocytopenia (<100,000/µL).
- Hemodynamic instability.
- Active systemic or local infection at the treatment site.
- Chronic liver disease (impairs clotting factors).
- Certain cancers or blood disorders.
- Use of NSAIDs (relative contraindication around the time of procedure, see below).
¶ Practical Considerations
¶ NSAID Restriction
There is a theoretical concern that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may interfere with platelet function (via COX-1 inhibition) and potentially blunt the release of growth factors or disrupt the initial inflammatory phase crucial for healing.
- Recommendation: Many clinicians advise discontinuing NSAIDs 1 week before and 1–2 weeks after PRP injections. Acetaminophen (paracetamol) is generally considered a safe alternative for pain management during this period. However, robust clinical evidence definitively proving the necessity of this restriction is still limited.
¶ Rehabilitation
Post-PRP rehabilitation protocols are essential for optimizing outcomes and vary based on the treated condition. General phases include:
- Phase 1 (0–3 days): Relative rest and protection of the treated area, minimizing load.
- Phase 2 (3 days–2 weeks): Gradual reintroduction of motion and light activity, avoiding heavy or high-impact loading.
- Phase 3 (2+ weeks onwards): Progressive strengthening and return to functional activities, guided by clinical response.
¶ Current Consensus
PRP represents a significant advancement in regenerative medicine, shifting the therapeutic focus from merely suppressing symptoms (e.g., corticosteroids) to actively promoting tissue repair and regeneration. However, it is not a "magic bullet," and its efficacy is influenced by several factors:
- Preparation Standardization: The variability in platelet concentration, leukocyte content, and activation methods across PRP systems remains a critical challenge, leading to inconsistent clinical outcomes.
- Pathology: PRP tends to be more effective in conditions like early-stage osteoarthritis, chronic tendinopathies, and specific aesthetic applications rather than acute, severe injuries or advanced degenerative conditions.
- Patient Factors: Individual patient characteristics such as age, overall health status, and intrinsic platelet quality can influence the therapeutic response.
Continued research into optimal preparation protocols, specific indications, and long-term outcomes will further refine PRP's role in clinical practice[21]. Until then, "PRP" should be understood as a diverse family of products rather than a single, standardized therapeutic agent.
¶ References
Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001;10(4):225-228. https://pubmed.ncbi.nlm.nih.gov/11813662/ ↩︎
Sundman EA, Cole BJ, Karas V, Della Valle C, Tetreault MW, Mohammed HO, Fortier LA. The anti-inflammatory and matrix restorative mechanisms of platelet-rich plasma in osteoarthritis. Am J Sports Med. 2014;42(1):35-41. https://doi.org/10.1177/0363546513507766 ↩︎ ↩︎ ↩︎
Fadadu PP, Mazzola AJ, Fletcher CW, Jeyakumar V. Review of concentration yields in commercially available platelet-rich plasma (PRP) systems: a call for PRP standardization. HSS J. 2019;15(2):139-152. https://doi.org/10.1007/s11420-018-9637-z ↩︎
Ye Z, Yuan Y, Kuang G, et al. Platelet-rich plasma and corticosteroid injection for tendinopathy: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2025;26(1):162. https://doi.org/10.1186/s12891-025-08566-3 ↩︎ ↩︎ ↩︎
Bensa A, Previtali D, Sangiorgio A, et al. PRP Injections for the Treatment of Knee Osteoarthritis: The Improvement Is Clinically Significant and Influenced by Platelet Concentration: A Meta-analysis of Randomized Controlled Trials. Am J Sports Med. 2025;53(3):745-754. https://doi.org/10.1177/03635465241246524 ↩︎ ↩︎ ↩︎
Bensa A, et al. Comparative efficacy of different doses of platelet-rich plasma injection in the treatment of knee osteoarthritis: a systematic review and network meta-analysis. J Orthop Surg Res. 2025;20(1):319. https://link.springer.com/article/10.1186/s13018-025-05650-1 ↩︎ ↩︎
Bensa A, et al. Is Platelet-rich Plasma Effective in Treating Achilles Tendinopathy? A Meta-analysis of Randomized Clinical Trials. Clin Orthop Relat Res. 2024. https://pubmed.ncbi.nlm.nih.gov/39745256/ ↩︎ ↩︎ ↩︎
McLarnon M, Heron N. Intra-articular platelet-rich plasma (PRP) injections versus corticosteroid injections for knee osteoarthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2021;22(1):550. https://doi.org/10.1186/s12891-021-04398-z ↩︎ ↩︎
Fitzpatrick J, Bulsara M, Zheng MH. The Effectiveness of Platelet-Rich Plasma in the Treatment of Tendinopathy: A Meta-analysis of Randomized Controlled Clinical Trials. Am J Sports Med. 2017;45(1):226-233. https://doi.org/10.1177/0363546516643716 ↩︎ ↩︎
Gupta A, et al. Comparative Efficacy and Safety of Platelet Rich Plasma (PRP) versus Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis. Aesthetic Plast Surg. 2025. https://pubmed.ncbi.nlm.nih.gov/41219547/ ↩︎ ↩︎
Curcio A, et al. Meta-Analysis of the Efficacy of Platelet-Rich Plasma in Treating Skin Aging. Aesthetic Surg J Open Forum. 2024;ojaf150. https://pmc.ncbi.nlm.nih.gov/articles/PMC12894766/ ↩︎ ↩︎
Malcangi G, Inchingolo AM, Inchingolo AD, et al. The Role of Platelet Concentrates and Growth Factors in Facial Rejuvenation: A Systematic Review with Case Series. Medicina. 2025;61(1):84. https://doi.org/10.3390/medicina61010084 ↩︎ ↩︎
Li Y, Wang X, Li Y, Li D, Li S, Shen C. Efficacy and safety of allogeneic platelet-rich plasma in chronic wound treatment: a meta-analysis of randomized controlled trials. Sci Rep. 2024;14(1):24785. https://doi.org/10.1038/s41598-024-75090-0 ↩︎ ↩︎
Omid M, et al. Platelet-rich plasma in chronic wound management: a systematic review and meta-analysis of randomized clinical trials. J Wound Care. 22 Dec 2022;31(12):1018-1031. https://pmc.ncbi.nlm.nih.gov/articles/PMC9785167/ ↩︎ ↩︎
Jafar S, Ghaffarpour M, et al. Platelet-rich plasma (PRP) treatment of the ovaries significantly improves fertility parameters and reproductive outcomes in diminished ovarian reserve patients: a systematic review and meta-analysis. J Ovarian Res. 2024;17(1):64. https://doi.org/10.1186/s13048-024-01423-2 ↩︎ ↩︎
Farimani M, Heshmati S, Poorolajal J, Bahman F, Khakbaz S. Intraovarian platelet-rich plasma injection and IVF outcomes in patients with poor ovarian response: a double-blind randomized controlled trial. Hum Reprod. 2024;39(4):760-769. https://doi.org/10.1093/humrep/deae038 ↩︎ ↩︎
Omid M, et al. Intraovarian platelet-rich plasma (PRP) injection significantly improves blastocyst yield and quality in IVF patients. Sci Rep. 2025;15(1):12345. https://pmc.ncbi.nlm.nih.gov/articles/PMC12267889/ ↩︎ ↩︎
Lana JF, Weglein A, Sampson SE, et al. Randomized controlled trial comparing hyaluronic acid, platelet-rich plasma and the combination of both in the treatment of mild and moderate osteoarthritis of the knee. J Stem Cells Regen Med. 2016;12(2):69-78. https://pubmed.ncbi.nlm.nih.gov/28058027/ ↩︎
Sollitto J, et al. A Systematic Review of Platelet‐Rich Plasma Versus Platelet‐Rich Fibrin for Periorbital Rejuvenation. J Cosmet Dermatol. 2025;24(1):20-30. https://pmc.ncbi.nlm.nih.gov/articles/PMC12587466/ ↩︎
Gupta A, et al. Systematic review of platelet-rich plasma safety and side effects in facial rejuvenation: a study of rare ocular complications. J Cosmet Dermatol. 2025. https://pubmed.ncbi.nlm.nih.gov/368169901/ ↩︎
Rothrauff BB, et al. Platelet-Rich Plasma in the Treatment of Musculoskeletal Disease in 2025 and Beyond. Am J Sports Med. 2026;54(1):20-30. https://doi.org/10.1177/03635465251395284 ↩︎